Here we report that targeting casein kinase 1-a1 (CSNK1a1) is a potential novel treatment strategy in multiple myeloma (MM) therapy distinct from proteasome inhibition. CSNK1a1 is expressed in all the tested MM cell lines and patient MM cells, and is not altered during bortezomib-triggered cytotoxicity. Inhibition of CSNK1a1 kinase activity in MM cells with targeted therapy D4476 or small hairpin RNAs triggers cell G0/G1-phase arrest, prolonged G2/M phase and apoptosis. D4476 also induced cytotoxicity in bortezomib-resistant MM cells and enhanced bortezomib-triggered cytotoxicity. CSNK1a1 signaling pathways include CDKN1B, P53 and FADD; gene signatures involved included interferon-a, tumor necrosis factor-a and LIN9. In addition, reduction of Csnk1a1 prevents cMYC/KRAS12V transformation of BaF3 cells independent of interleukin-3. Impartially, reducing Csnk1a1 prevented development of cMYC/KRAS12V-induced plasmacytomas in mice, suggesting that CSNK1a1 may be involved in MM initiation and progression. Our data suggest that targeting CSNK1a1, alone or combined with bortezomib, is a potential novel therapeutic strategy in MM. Moreover, inhibition of CSNK1a1 may prevent the progression of monoclonal gammopathy of undetermined significance to MM.
INTRODUCTION
Multiple myeloma (MM) is a plasma cell neoplasm characterized by the accumulation of monoclonal plasma cells in bone marrow and monoclonal protein in serum and urine, associated with bone fractures, anemia, kidney dysfunction, hypercalcemia and immunodeficiency. 1 Currently, all newly diagnosed patients receive novel immune-modulating drugs (Thalidomide/Lenalidomide) and/or proteasome inhibitors (bortezomib). 2, 3 In spite of these therapies, development of resistance and relapse remain major treatment challenges, 4 and novel targeted MM therapies are urgently needed.
Pathologic activation of MYC family members plays a critical role in MM pathogenesis and relapse. 5 Amplification of MYC associated with progression from monoclonal gammopathy of undetermined significance (MGUS) to MM for MYC 6 and the high frequency of MYC deregulation family members in MM suggest that MYC is an attractive therapeutic target. Moreover, previous studies already demonstrated that targeting MYC significantly inhibited MM cell survival both in vitro and in vivo. 7 However, MYC family members play essential functions in proliferative tissues, 8 and inhibiting MYC activity for long period could cause toxicity. An alternative strategy to target MYC signaling is to inhibit its partner functions. For example, previous studies indicated that interaction between MYC and casein kinase 1 (CSNK1) family members, and that targeting CSNK1 family member can halt MYC-driven cancer growth. 9, 10 CSNK1 kinase family members are serine/threonine-specific protein kinases including seven mammalian isoforms (a, b, g1, g2, g3, d and e) and their various splice variants. 11 CSNK1 family members are involved in multiple cellular processes including gene transcription, DNA repair, cell division, nuclear localization and membrane transport. 11 Analysis of gene profiling shows increased expression of CSNK1a1 in most newly diagnosed MM compared with MGUS. 12, 13 CSNK1a1 has also been shown to be involved in other signaling pathways, such as Wnt signaling.
Specifically, ablation of Csnk1a1 stabilizes b-catenin and increases transcription of Wnt target genes. 9 More increasing evidences support that Csnk1a1 plays positive roles in tumor pathogenesis and is a potential target for tumor therapy. 14 Csnk1a1 negatively regulates tumor suppressor genes by directly or indirectly interacting with these proteins. For example, Csnk1a1 physically interacts with Mdm2 (murine double minute chromosome2) oncogene resulting in degradation of p53. [15] [16] [17] CSNK1a1 also negatively regulates apoptosis; CSNK1a1 phosphorylates p75 tumor necrosis factor (TNF) and FADD (Fas-Associated protein with Death Domain), thereby impeding their apoptotic activities. 18, 19 CSNK1a1 regulates Fas-mediated apoptosis through phosphorylation of Bid that prevents caspase 8-dependant cleavage of Bid and inhibits Fas response. 20 Finally, CSNK1a1 interacts and/or phosphorylates RXR to modulate RXR agonist-mediated apoptosis that prevents cytochrome c releasing from the mitochondria. 21 To date, the functions of CSNK1a1 in MM pathogenesis and disease progression are not defined. Here we report that CSNK1a1 is critical for MM cell survival and represent a novel therapeutic target.
MATERIALS AND METHODS

Cell lines and MM patient cells
Human MM cell lines including MM1S, RPMI 8226, U266, MM1R, OPM1, OPM2, INA6, ANBL6, ANBL-6VR, LR5 and RPMI-DOX40 (DOX40) are maintained and cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum and 100 units/ml penicillin/streptomycin. INA6, ANBL6 and ANBL-6VR also require 2 ng/ml interleukin-6; and ANBL-6VR line is cultured with 2.5 nM bortezomib. CD138 þ tumor cells were purified from bone marrow aspirates of MM patients. BaF3 cells are cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum, 100 units/ml penicillin/streptomycin, 50 mM b-mercaptoethanol and 10% WEHI3 cell culture supernatant.
Immunoblotting
Whole cells were lysed with RIPA buffer plus protease and phosphatase inhibitors. Proteins were separated with 4-15% PAGE gel electrophoresis, transferred onto membranes and immunoblotted with primary antibodies; followed by incubation with horseradish peroxidase-conjugated secondary antibodies. Final signal is detected with enhanced chemiluminescence.
Cell biological assays
In all cell assays, final cell concentration was 1 Â 10 5 cells/ml. Bortezomib and D4476 were dissolved in dimethyl sulfoxide and stored at -20 1C. For sell viability assay, MM cells were seeded in triplicate into 96-well plates in 100 ml culture media. D4476 was added to each well at concentrations of 0, 5, 10, 20, 30, 40 and 50 mM in another 100 ml culture media. Cell viability was measured with 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) at the 72 h drug exposure. Absorbance was measured at 570 nm with spectrophotometer.
MM cells were exposed to dimethyl sulfoxide or D4476 at 10, 20 and 30 mM. For cell apoptosis analysis, cells were harvested at 72 h and stained with fluorescein isothiocyanate-conjugated annexin V and propidium iodide for Flow Cytometric analysis. For cell cycle analysis, cells were harvested at 24 h and permeabilized with 5 ml 70% ethanol on ice for 30 min, resuspended with 1 ml staining solution (phosphate-buffered saline containing 0.1% Triton X-100, 50 mg/ml propidium iodide and 20 units/ml RNase-A) and incubated at 371 C for 30 min. Cell cycle was analyzed with Flow Cytometry using Watson model.
Lentiviral stocks and cell transfection
Lentiviral-based small hairpin RNA (shRNA) vectors include one control vector (shRNA sequence targeting Lactose gene) and five shRNAs designed specifically against CSNK1a1. To produce virus, constructs were co-transfected with packaging vectors (psPAX2 and MD2.G) into 293T cells. Viral supernatant was collected at 48 h. For each sample, 3 million cells were resuspended with viral transfection medium (2 ml cell culture medium, 2 ml viral stocks, 40 ml HEPES, pH 7.4, and 2 mg/ml polybrene) and centrifuged at 1000 g for 90 min in 6-well plates. After another 3 h of culture, cells were transferred to 25 cm 2 flasks with 10 ml fresh medium. All processes were performed in a BL2lenti room.
Gene expression profiling
Total RNA was extracted with RNA mini kit, and gene expression profiling was performed with the Affymetrix (Santa Clara, CA, USA) Human Gene 2.0 ST chips. Microarray data were analyzed with Bioconductor oligo and OncchannelGUI packages in R workplace (Institute for Statistics and Mathematics, Welthandelsplatz, Wien, Austria). Differential expression was determined using LIMMA model. Gene signatures were analyzed with Gene Set Enrichment Analysis (GSEA) in Molecular Signatures Database (MSigDB, Broad Institute, Cambridge, MA, USA).
DNA constructs
The retroviral vectors (MIGm, MIKMG) were generated as previously described. 22 The MIGmI vector was created by inserting a specific sequence (5 0 -GATCGTTTAAAGGGAGGTAGTGAGTCGACCAGTAGATCTCTCG AGGATATCTAGACCCAGCTTTCTTGTACAAAGTGGTTGATCTAGAGGGCCCGCG GTTCGCTGATGTCGA-3 0 ) into MIGm vector at BglII/XhoI sites. The RNAi sequences specifically targeting mouse Csnk1a1 (5 0 -GCAGAATTTGCCATGTA CTTA-3 0 and 5 0 -GCTGTACGAGAGCAAACTGTA-3 0 ) were cloned into pcDNA6.2-GW/EmGFP-miR vector, and then were cut off with BamHI/XhoI and inserted into MIGmI vector to obtain MIGmICsnk1a1Rs. Oncogenic cassette (cMYC-2a-eGFP-IRES-KRAS12V) was cut from MIKMG with restriction enzymes SpeI and NotI, and then inserted into MIGmI Csnk1a1Rs at same enzyme digesting sites to obtain MKCsnk1a1R1 and MKCsnk1a1R2. Knockdown efficiency was assessed following retroviral transduction into BaF3 cells, as previously described. 22 
Mouse model
The procedures for retroviral transfection and transplantation in the PCT mouse model, as well as phenotypic analysis, were referred as in previous studies. 22 
Statistics
All in vitro experiments were performed in triplicate and repeated at least 3 times. Statistical significance was determined with t-tests, with minimal significance level Po0.05 using GraphPad Prism software (La Jolla, CA, USA). 
RESULTS
Inhibiting CSNK1a1 activity impaired MM cell survival
Previous studies have reported that CSNk1a1 is highly expressed in many kinds of cancers and is a potential target for cancer chemotherapy. 14 In MM studies, gene expression profiling revealed that CSNk1a1 was highly expressed in MM and plasma cell leukemia patients compared with MGUS and normal plasma cells. 12, 13, 23 Consistent with gene expression results, we confirmed that CSNk1a1 protein was presented in all examined MM cell lines and CD138 þ MM patient cells (Figures 1a and b ).
To evaluate whether CSNK1a1 represents a novel target for MM therapy, we next treated MM lines with D4476, a CSNK1a1 inhibitor. 24, 25 We found that D4476 induced cytotoxicity in ANBL6, INA6 and RPMI 8226 lines; MM1S and U266 lines were less sensitive; and OPM1 line was totally resistant. High concentrations (50 mM) of D4476 induced toxicity in all MM lines ( Figure 1c ). Inhibition of CSNK1a1 activity reduced cells entering S phase and prolonged G2/M phase, as well as induced MM cell apoptosis (Figures 1d and e ).
Previous studies showed that D4476 selectively inhibits CSNK1a1 as well as inhibits TGF-b type-I receptor (ALK5) activity. 24 To verify the function of CSNK1a1 in MM cells, we used shRNA to specifically knock down CSNK1a1. The biological efficiency of shRNAs in reducing CSNK1a1 protein was tested in RPMI 8226 cells: relative to control vector and other shRNAs, shRNA3 and shRNA5 showed most efficient CSNK1a1 targeting (Figure 2a ). Importantly, downregulation of CSNK1a1 with shRNA3 or shRNA5 significantly decreased MM cell survival and proliferation (Figure 2b) . As with D4476, downregulation of CSNK1a1 with shRNAs reduced cells entering S-phase arrest and prolonged G2/M phase, as well as induced apoptosis (Figures 2c and d) . These results suggest that CSNK1a1 plays a critical role in MM cell survival.
Inhibition of CSNK1a1 causes upregulation of TP53, P21 and FADD. 9, 18 After MM cells were exposed to D4476, protein levels of TP53, P27 and FADD were increased ( Supplementary Figures S1A  and B ), associated with cell cycle progression and induction of apoptosis. TP53 is mutant in both RPMI 8226 and ANBL6 lines, and therefore TP53 signaling is unlikely to mainly contribute to the cytotoxicity.
To further delineate the role of CSNK1a1 in MM cells, we compared gene transcription changes in RPMI 8226 cells transfected with control vector, versus shRNA3 and shRNA5. CSNK1a1 is potential target for MM therapy Y Hu et al CSNK1a1 mRNAs were also evaluated with reverse transcriptase-PCR. Consistent with immunoblotting results, both shRNA3 and shRNA5 significantly reduced CSNK1a1 mRNA level (Figure 3a ). In this analysis, gene expression profiling of shRNA3 and shRNA5 was evaluated with GSEA. GSEA demonstrated that genes upregulated by interferon-a (IFNa) in ovarian cancer progenitor cells 26 were significantly upregulated and enriched by shRNA3 and shRNA5 in RPMI 8226 cells (Figure 3b ), suggesting that targeting CSNK1a1 may induce antitumor effects similar to IFNa. We selected six genes (DDX60, IFIH1, IFI44L, IFIT1, MX1 and SAMD9L), which are ranked with higher score in GSEA analysis gene list, to represent the gene signature. Consistent with microarray data, all six genes were upregulated in reverse transcriptase-PCR analysis (Figure 3c ). To further confirm the mechanism whereby inhibition of CSNK1a1 induced cytotoxicity, we treated RPMI 8226 and ANBL6 cells with D4476 (30 mM for 24 h) and examined gene transcription pattern changes by reverse transcriptase-PCR in both RPMI 8226 and ANBL6 cells (Figures 3d and e ). These results show that inhibition of CSNK1a1 activity with either shRNAs or D4476 induced cytotoxicity via a mechanism similar to IFNa .
Several other CSNK1a1 gene signatures were also identified. For example, genes in IRF4 signature were significantly enriched and downregulated after CSNK1a1 inhibition by shRNA3 and shRNA5 (Supplementary Figure S2A) . 27 Genes in LIN9 signaling regulating cell mitosis were also enriched and downregulated, consistent with the observation that inhibition of CSNK1a1 activity blocks cell mitosis, prolonging G2/M phages (Supplementary Figure S2B ). 28 We also found that TNFa 29 and STAT3 (ref. 30 ) gene sets were significantly upregulated and enriched after CSNK1a1 knockdown by shRNA3 and shRNA5 ( Supplementary Figures S2C and D) . Factors impeding the cytotoxicity effects of targeting CSNK1a1 in MM cells OPM1 cells were resistant to D4476-triggered cytotoxicity, whereas MM1S and U266 cells were less sensitive. To delineate the potential mechanisms of resistance, MM1S and OPM1 lines were treated with either D4476 (30 mM) or equal concentrations of dimethyl sulfoxide for 24 h. Total RNA was extracted and mRNA changes of the six selected genes were examined with reverse transcriptase-PCR. Compared with RPMI 8226-sensitive cell line, four of six genes were slightly upregulated and two genes were downregulated in MM1S cells. In OPM1 line, three genes were downregulated, two genes were slightly upregulated and one gene showed no changes (Figure 4a and Supplementary  Table S1 ). OPM1 line was established from a patient with t(4;14) translocation MM in which fibroblast growth-factor receptor 3 (FGFR3) gene is involved in pathogenesis. 31, 32 To examine whether FGFR3 confers OPM1 line resistance, we ectopically expressed FGFR3 in RPMI 8226 cells and established a FGFR3stable transfection cell line, named RPMI-FGFR3. Importantly, RPMI-FGFR3 remains sensitive to D4476-induced cytotoxicity CSNK1a1 is potential target for MM therapy Y Hu et al (Figure 4b ), suggesting that OPM1 resistance to D4476 is not due to FGFR3.
Targeting CSNK1a1 overcame bortezomib resistance and enhanced bortezomib-induced cytotoxicity
To test whether targeting CSNK1a1 could overcome bortezomib resistance, a bortezomib-resistant line, ANBL6-VR5, 33 was treated with D4476. D4476 significantly impaired ANBL6-VR5 cell survival (Figure 4c ), suggesting that targeting CSNK1a1 can overcome bortezomib resistance. To verify whether inhibiting CSNK1a1 with D4476 could strengthen bortezomib-triggered cytotoxicity on MM cells, we first treated MM cells with bortezomib (0-20 nM) for 12 h or with bortezomib (20 nM) for 0-8 h. Although proteasome activity was significantly inhibited, CSNk1a1 protein was not affected (Figure 4d ), suggesting that CSNk1a1 is worthy to be targeted in bortezomib-triggered cytotoxicity. Then, we treated RPMI 8226 cells with both D4476 and bortezomib and found that the combination triggered an additive cytotoxicity in MM cells (Figure 4e ).
CSNK1a1 is required for cMYC/KRAS12V-induced plasamacytomas (PCTs) in vivo
Our previous studies have shown that transfection of cMYC with KRAS12V can induce PCTs in BABL/c mice. 22 Based on previous reports, Ras increases CSNK1a1 activity via MEKK1. 34, 35 To determine whether Csnk1a1 plays a role in cMYC/KRAS12Vinduced PCT genesis, we expressed cMYC/KRAS12V and inhibited Csnk1a1 in targeted cells using the same vector. Specifically, we generated two of this kind of constructs (MKCsnk1a1R1 and MKCsnk1a1R2) for these studies (Figure 5a ). To examine whether the shRNA cassette affects its upstream oncogene expression, we transiently transfected 293T cells with these constructs and examined gene expression with immunoblotting. The shRNA cassette does not affect KRAS12V, cMYC and GFP expression ( Figure 5b ) (GFP expression was observed by microscopy). To examine biological sequelea, MK, MKCsnk1a1R1 and MKCsnk1a1R2 were retrovirally transfected into BaF3 cells. GFP þ cells were sorted at 48 h post viral transduction, then cultured for 48 h and passed to harvesting and immunoblotting against Csnk1a1. Csnk1a1 level was obviously decreased in MKCsnk1a1R1-transduced cells, but not MK or MKCsnk1a1R2transfected BaF3 cells ( Figure 5c ); and MKCsnk1a1R1 could not drive BaF3 cell growth independent of IL3, as did MK and MKCsnk1a1R2 (Figure 5d ). These data indicated that Csnk1a1 is required for cMYC/KRAS12V-driven BaF3 cell growth independent of interleukin-3.
To determine whether MKCsnk1a1R1 can transform BALB/c T2 B cells and induce PCTs in vivo, we transplanted cells transfected with MK or MKCsnk1a1R1 into lethally irradiated syngeneic recipient mice. Recipients receiving MK-transduced cells developed lethal PCTs by 39 days post transplantation. Recipients receiving MKCsnk1a1R1-transfected cells remained healthy at 20 weeks post transplantation (Figure 6a ). Consistent with previous data, 22 mice receiving MK-transduced cells died with lethal PCTs characterized by peritoneal tumor, ascites and enlarged spleen as in previous studies. 22 Bone marrow and spleen cells were isolated from MK and MKCsnk1a1R1 group mice and analyzed for the expression of GFP and CD138 by flow cytometry. Importantly, there were no tumor cells (GFP þ CD138 þ ) detectable in MKCsnk1a1R1 group samples (Figure 6b ). Consistent with fluorescence-activated cell sorting results, PCT cells only developed in MK but not in MKCsnk1a1R1 group mice (Figure 6c ). These results suggest that downregulation of Csnk1a1 can prevent MYC/KRAS12V-induced PCTs in BALB/c mice.
DISCUSSION
Casein kinase family members are attractive targets in cancers chemotherapies, including myeloma. 10, 36, 37 However, there is no any study about CSNK1a1 in MM. In this study, we demonstrated that CSNK1a1 is present in patient MM cells and MM lines. Inhibition of CSNK1a1 activity by either inhibitor (D4476) or shRNAs causes G0/G1phase arrest, prolongs G2/M phase and induces apoptosis in some MM cell lines. Targeting CSNK1a1 signaling affects several classic cell proliferation and apoptosis pathways including CDKN1B, P53, FADD, IFNa, TNF and LIN9 in MM cells. Specifically, CSNK1a1 suppresses P53 activity by altering its phosphorylation status, as well as increases MDM2 activity. 17 However, our results suggest that P53 does not play a critical role in CSNK1a1-triggered cytotoxicity, as RPMI 8226 cell with P53 temperature-sensitive mutation (E285K) 38 are more sensitive to D4476 or CSNK1a1 shRNA than MM1S cells with wild-type P53.
To further reveal the potential pathways involved in CSNK1a1 signaling, we compared gene expression profiling of RPMI 8226 cells transfected with either control vector or with CSNK1a1 shRNA3 and shRNA5. Genes modulated by IFNa and TNFa are significantly upregulated and enriched by CSNK1a1 knockdown. The antiproliferative effects of IFNa are associated G0/G1 phase blocked and S-phase prolonged, 39 as is observed in MM cells treated with D44476 or transfected with CSNK1a1 shRNAs. In previous reports of IFNa clinical studies, 5-10% of MM patients obtained a significant prolongation in event-free survival and overall survival. 40 Our in vitro studies also show that only certain MM cell lines are sensitive to CSNK1a1 inhibitor or shRNAs. To date, however, there is no biomarker to identify those patients who are likely to benefit from IFNa treatment. 40 Based on our studies, we hypothesized that expression of genes in the IFNa signature may identify these patients. 29 To test this hypothesis, we compared the expression of these genes among RPMI 8226, MM1S and OPM2 MM cell lines (GSE22759 at Gene Expression Omnibus database). As expected, most IFNa signature genes are expressed highly in RPMI 8226 cells, moderately in MM1S cells and weakly in OPM2 cells (Supplementary Figure S3 ). These data suggest that patients with MM cells that highly express these genes may well respond to either IFNa or inhibition of CSNK1a1 treatment.
Before investigating the roles of CSNK1a1 in MM, we analyzed its expression in MM patients using Oncomine database system (https://www.oncomine.org/). CSNK1a1 was highly expressed in smoldering myeloma versus normal plasma cells, 13 and its expression was significantly increased in MM or plasma cell leukemia patients compared with MGUS (Supplementary Figure S4 ). 12, 13, 23 These data suggest a role of CSNK1a1 in the progression of MGUS to MM. To examine this possibility, we used our retroviral transfection/transplantation PCT mouse model. 22 Specifically, we used cMYC and KRAS12V transfection to drive PCT formation, as previous studies indicate that dysregulation or mutants of cMYC and RAS play major roles in progression from MGUS to MM and MM relapse. 41 Moreover, CSNK1a1 is not only involved in MYC signaling, but also in RAS signaling via MEKK1. 34, 35 Our in vitro data show that cMYC/KRAS12V without Csnk1a1 could not promote BaF3 growth independent of interleukin-3, suggesting that Csnk1a1 plays an important role in cell transformation by MYC and RAS. Furthermore, our in vivo results demonstrate that inhibiting Csnk1a1 prevents development of cMYC/KRAS12V-induced PCTs in mice. These results indicate that Csnk1a1 is required for cMYC/KRAS12Vinduced development of PCTs in mice, and suggest a role of CSNK1a1 in progression from MGUS to MM, especially in MM with cMYC or KRAS dysregulation. Our studies therefore delineate the role of CSNK1a1 in MM pathogenesis and provide the framework for clinical evaluation of CSNK1a1 inhibitors to treat MM as well as to prevent progression from MGUS to MM.
